China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Independent Clinical Medical and Laboratory Services, and Other Business segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.
China Isotope & Radiation Dividend Announcement
• China Isotope & Radiation announced a quarterly dividend of HK$0.07 per ordinary share which will be made payable on 2024-11-22. Ex dividend date: 2024-09-27
• China Isotope & Radiation annual dividend for 2024 was HK$0.73
• China Isotope & Radiation annual dividend for 2023 was HK$0.48
• China Isotope & Radiation's trailing twelve-month (TTM) dividend yield is 6.31%
• China Isotope & Radiation's payout ratio for the trailing twelve months (TTM) is 35.37%
• China Isotope & Radiation's dividend growth over the last five years (2018-2023) was 23.10% year
China Isotope & Radiation Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-09-27 | HK$0.07 | quarterly | 2024-11-22 |
2024-06-19 | HK$0.34 | quarterly | 2024-08-13 |
2024-06-12 | HK$0.31 | quarterly | 2024-08-06 |
2023-07-04 | HK$0.48 | quarterly | 2023-08-31 |
2022-05-25 | HK$0.44 | quarterly | 2022-07-22 |
2021-05-17 | HK$0.22 | quarterly | 2021-07-26 |
2020-07-06 | HK$0.15 | quarterly | 2020-08-28 |
2019-07-03 | HK$0.14 | quarterly | 2019-08-28 |
2018-11-28 | HK$0.17 | quarterly | 2019-01-31 |
China Isotope & Radiation Dividend per year
China Isotope & Radiation Dividend growth
China Isotope & Radiation Dividend Yield
China Isotope & Radiation current trailing twelve-month (TTM) dividend yield is 6.31%. Interested in purchasing China Isotope & Radiation stock? Use our calculator to estimate your expected dividend yield:
China Isotope & Radiation Financial Ratios
China Isotope & Radiation Dividend FAQ
Other factors to consider when evaluating China Isotope & Radiation as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy China Isotope & Radiation stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: China Isotope & Radiation's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, China Isotope & Radiation publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, China Isotope & Radiation distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from China Isotope & Radiation are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: China Isotope & Radiation sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, China Isotope & Radiation distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: China Isotope & Radiation declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of China Isotope & Radiation's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review China Isotope & Radiation's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.